Zurcher Kantonalbank (Zurich Cantonalbank) Genmab A/S Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$34.1 Billion
Q4 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	SELL	$26.43 - $32.77 $8,431 - $10,453	-319 Reduced 99.69%	1 $0
Q4 2023 Jan 30, 2024	SELL	$27.94 - $35.44 $1,145 - $1,453	-41 Reduced 11.36%	320 $10,000
Q3 2023 Oct 25, 2023	SELL	$35.27 - $42.24 $4,197 - $5,026	-119 Reduced 24.79%	361 $12,000
Q2 2023 Aug 07, 2023	SELL	$37.4 - $42.94 $4,114 - $4,723	-110 Reduced 18.64%	480 $18,000
Q1 2023 May 08, 2023	BUY	$34.88 - $43.22 $20,579 - $25,499	590 New	590 $22,000

Others Institutions Holding GMAB

# of Institutions

233

Shares Held

52.2M

Call Options Held

10.2K

Put Options Held

25.5K

Alliancebernstein L.P. New York, NY

15.1M
Shares

$288 Million
0.13% of portfolio
Black Rock Inc. New York, NY

5.08M
Shares

$96.5 Million
0.0% of portfolio
Capital International Investors Los Angeles, CA

4.42M
Shares

$84 Million
0.02% of portfolio
Harding Loevner LP Bridgewater, NJ

3.07M
Shares

$58.3 Million
0.44% of portfolio
Wellington Management Group LLP Boston, MA

2.31M
Shares

$43.8 Million
0.01% of portfolio

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $12.5B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account